|Last Update: 05/21/13 - 4:00 PM EDT|
|YTD Performance: 13.46%|
|Previous Close: $112.02|
|52 Week Range: $82.26 - $113.19|
|Oustanding Shares: 436,371,394|
|Market Cap: 48,882,323,556|
|Qtr (05/13)||Qtr (08/13)||FY (08/13)||FY (08/14)|
|Number of Analysts||14||13||17||16|
|Growth Rate (Year over Year)||16.23%||5.48%||15.00%||10.63%|
COST estimates were boosted through 2014, UBS said. SKU productivity remains better than the competition. Buy rating and $121 price target.
Some believe recent economic data prove the consumer will be wilting.
COST was initiated with a Buy rating, said UBS. Membership fees will drive reliable profit growth. Price target is $121.
Here are some names that can be bought during this orderly pullback.
Jim Cramer discusses the implications of CEO departures with Nicole Urken, research director for Mad Money
The really bad stuff that you might be cycling into will simply not hold up as well on the pullback.
Merck is Dow's best performer, Nasdaq and S&P slightly lower. TheStreet's David Peltier has more on the mid-morning action.
Stock index futures are pointing to a lower open on Wall Street as analysts cut estimates on Google at Oppenheimer. TheStreet's David Peltier has Tuesday's premarket action.
There’s reason to suspect the recent positive numbers could be an outlier.
The complacency is thick in the air.